Acumen Pharmaceuticals Inc

ABOS.US
Healthcare · Biotechnology
2.28
+0.08 (+3.64%)
USD · NASDAQ

Company Information

Company Name
Acumen Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00509G2093
CIK: 0001576885
CUSIP: 00509G209
Currency: USD
Full Time Employees: 60
Phone: 617 344 4190
Fiscal Year End: December
IPO Date: Jul 01, 2021
Description:

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Address:

1210-1220 Washington St., Newton, MA, United States, 02465

People

Directors & Officers

Name Title Year Born
Mr. Daniel J. O'Connell M.B.A. CEO & Director 1970
Dr. James Doherty Ph.D. President & Chief Development Officer 1968
Mr. Matt Zuga CFO & Chief Business Officer NA
Dr. Grant A. Krafft Ph.D. Co-Founder NA
Dr. Caleb E. Finch Ph.D. Co-Founder NA
Dr. William L. Klein Ph.D. Co-Founder NA
Mr. Russell Barton M.S. Chief Operating Officer 1959
Ms. Kelly Carranza Senior Vice President of Finance & Accounting and Corporate Controller NA
Ms. Alex Braun M.B.A. VP & Head of Investor Relations NA
Mr. Derek M. Meisner Esq., J.D. Chief Legal Officer & Corporate Secretary 1971

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 22, 2026 Eric Siemers N/A Sale 895.00 $1.82 $1.63K
Jan 22, 2026 Matt Zuga N/A Sale 1.69K $1.86 $3.14K
Jan 22, 2026 Russell Barton N/A Sale 462.00 $1.84 $850.08
Jan 22, 2026 Daniel Joseph Oconnell N/A Sale 2.69K $1.88 $5.06K
Jan 21, 2026 Daniel Joseph Oconnell N/A Sale 9.35K $1.81 $16.92K
Jan 21, 2026 Eric Siemers N/A Sale 2.33K $1.80 $4.20K
Jan 21, 2026 Matt Zuga N/A Sale 2.47K $1.81 $4.48K
Jan 21, 2026 Russell Barton N/A Sale 2.32K $1.81 $4.19K
Jan 12, 2026 Daniel Joseph Oconnell N/A Sale 5.39K $1.73 $9.32K
Jan 09, 2026 Daniel Joseph Oconnell N/A Sale 12.94K $1.76 $22.78K
Jan 08, 2026 Russell Barton N/A Sale 3.53K $1.86 $6.57K
Jan 08, 2026 Matt Zuga N/A Sale 6.89K $1.82 $12.54K
Jan 08, 2026 James J Doherty N/A Sale 6.47K $1.82 $11.77K
Jan 08, 2026 Daniel Joseph Oconnell N/A Sale 8.14K $1.82 $14.82K
Jan 07, 2026 Daniel Joseph Oconnell N/A Sale 37.76K $1.99 $75.13K
Jan 07, 2026 James J Doherty N/A Sale 1.70K $1.99 $3.38K
Jan 07, 2026 Matt Zuga N/A Sale 5.81K $1.99 $11.55K
Jan 07, 2026 Russell Barton N/A Sale 1.70K $1.99 $3.38K
Jan 06, 2026 Daniel Joseph Oconnell N/A Sale 5.10K $1.97 $10.05K
Jan 06, 2026 Eric Siemers N/A Sale 6.83K $1.97 $13.46K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 20.99M Mar 31, 2026 29.06% $0.52 40.59%
Sands Capital Ventures, LLC 3.72M Mar 31, 2026 5.15% $2.08 8.87%
Alyeska Investment Group, L.P. 2.45M Mar 31, 2026 3.40% $0.02 161.25%
Franklin Resources Inc 2.31M Mar 31, 2026 3.19% $0.00 0.00%
ADAR1 Capital Management LLC 2.16M Mar 31, 2026 2.99% $0.30 141.96%
Vanguard Group Inc 1.65M Dec 31, 2025 2.29% $0.00 0.14%
Knollwood Investment Advisory LLC 1.63M Mar 31, 2026 2.25% $0.39 0.00%
Vanguard Capital Management, LLC 1.51M Mar 31, 2026 2.09% $0.00 0.00%
FMR Inc 1.16M Mar 31, 2026 1.60% $0.00 -42.92%
Ikarian Capital, LLC 1.05M Mar 31, 2026 1.46% $0.20 314.37%
Hudson Bay Capital Management LP 968.94K Mar 31, 2026 1.34% $0.01 33.65%
Pathstone Holdings LLC 859.11K Mar 31, 2026 1.19% $0.01 0.00%
SG Americas Securities, LLC 719.26K Mar 31, 2026 1.00% $0.00 79.34%
Millennium Management LLC 659.68K Mar 31, 2026 0.91% $0.00 12.93%
Susquehanna International Group, LLP 601.48K Mar 31, 2026 0.83% $0.00 61.17%
Two Sigma Investments LLC 530.81K Mar 31, 2026 0.73% $0.00 270.62%
LAURION CAPITAL MANAGEMENT LP 525.44K Mar 31, 2026 0.73% $0.05 -39.40%
Renaissance Technologies Corp 473.95K Mar 31, 2026 0.66% $0.00 12.02%
Two Sigma Advisers, LLC 421.80K Dec 31, 2025 0.58% $0.00 -0.42%
Geode Capital Management, LLC 416.24K Mar 31, 2026 0.58% $0.00 1.47%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Franklin Biotechnology Discv A(acc)USD 1.48M 2.05% ▲ 0.00% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 1.12M 1.55% ▲ 0.00% Jun 30, 2026
3 iShares Russell 2000 ETF 1.04M 1.44% ▲ 0.60% Jun 30, 2026
4 Franklin Biotechnology Discovery A 826.40K 1.14% ▲ 0.00% Jun 30, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 513.51K 0.71% ▲ 36.88% Jun 30, 2026
6 iShares Russell 2000 Value ETF 427.14K 0.59% ▼ 0.69% Jun 30, 2026
7 Russell 2000 Index Non-Lendable Fund 295.87K 0.41% ▲ 0.00% Jun 30, 2026
8 Russell 2000 Equity Index Fund B 295.87K 0.41% ▲ 0.00% Jun 30, 2026
9 Vanguard Russell 2000 ETF 273.22K 0.38% ▲ 0.00% Jun 30, 2026
10 Fidelity Extended Market Index 177.19K 0.25% ▼ 4.79% May 31, 2026

Financial Highlights

Market Cap: $158.90M
EBITDA: $-114.56M
Book Value: $1.21
Earnings/Share: $-1.92
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -42.37%
ROE (TTM): -93.23%
Revenue (TTM): $329.00K
Revenue/Share (TTM): $0.03
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $56.61M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 72.23M
Shares Float: 36.96M
% Insiders: 680.10%
% Institutions: 6,463.80%
Short % Float: 5.59%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-184.00K
Gross Profit
subtotal
$-184.00K
SG&A
adjust
$-18.95M
R&D
adjust
$-104.89M
Operating Income
subtotal
$-123.83M
Other / Non-Operating Items
adjust
$2.50M
Net Income
subtotal
$-121.34M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ABOS.US!